Back to all discussions


RAGE Biotech is developing new approaches to modulate the receptor for advanced glycation end- products (RAGE), an important target in chronic inflammation with links to COPD and cystic fibrosis.

“Inflammation is the driving force in many important diseases,” Professor Thomas said.

“RAGE is a key protein that amplifies inflammation, so targeting RAGE helps bring inflammation back under control.

“Often it’s not easy to turn inflammation down without disrupting pathways needed for good health. But RAGE only turns up when things are going wrong, which makes it such a great target.”

RAGE Biotech will test two novel approaches to modulate RAGE.

  1. Me too.

    1. I don't think there are any updates on their website. I hope something comes up soon.

      1. No progress info is available on their website. Last news mentioning them is from July 2020.

        Hope they didn't go quietly into the night like so many others.

        1. Check it in radiobiotech dot com

          or create an account to reply.